J Clin Oncol:2型糖尿病女性长期使用长效胰岛素与乳腺癌发生率的关系

2017-10-24 男男和北北 恒兴医讯

甘精胰岛素与乳腺癌风险增加相关(HR,1.44;95%CI,1.11-1.85),主要是在甘精胰岛素开始使用后5年(HR,2.23;95%CI,1.32-3.77)和超过30次处方后5年(HR,2.29;95%CI,1.26-4.16)乳腺癌风险增加。在既往胰岛素使用者中这种风险增加特别高(HR,1.53;95%CI,1.10-2.12),但对于胰岛素新使用者没有增加,但由于纳入的胰岛素新使用者较

美国《临床肿瘤杂志》2017年9月27日在线先发:2型糖尿病女性长期使用长效胰岛素与乳腺癌发生率的关系。

目的

长效胰岛素与乳腺癌风险增加之间的相关性尚不明,特别是既往的短期随访研究没有阐明。为此,我们评价了2型糖尿病女性这种长期风险。

方法

采用英国“临床实践研究数据链”,构建一个以人群为基础的≥40岁女性的队列,队列中所有人2002年至2012年间进行了长效(甘精胰岛素、地特胰岛素)或中效低精蛋白胰岛素(NPH)治疗。对这些女性随访至2015年2月或乳腺癌诊断时。采用Cox比例风险模型估算新发乳腺癌校正后的风险比(HRs)和95%CI,通过用药持续时间和累计剂量比较了长效胰岛素和中效低精蛋白胰岛素(NPH)。

结果

这个队列纳入22395名接受胰岛素治疗的女性,长达12年的随访期间出现321个新发乳腺癌事件(新发率为3.3/1000人年)。与中效低精蛋白胰岛素(NPH)相比,甘精胰岛素与乳腺癌风险增加相关(HR,1.44;95%CI,1.11-1.85),主要是在甘精胰岛素开始使用后5年(HR,2.23;95%CI,1.32-3.77)和超过30次处方后5年(HR,2.29;95%CI,1.26-4.16)乳腺癌风险增加。在既往胰岛素使用者中这种风险增加特别高(HR,1.53;95%CI,1.10-2.12),但对于胰岛素新使用者没有增加,但由于纳入的胰岛素新使用者较少而无法排除1.81的风险比。与地特胰岛素相关这种乳腺癌风险没有明显增加(HR,1.17;95%CI,0.77-1.77)。

结论

在2型糖尿病女性中,长期使用甘精胰岛素与乳腺癌风险增加相关,由于地特胰岛素使用者少,地特胰岛素与乳腺癌风险的相关关系尚不明确。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1826387, encodeId=da74182638ea9, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Jul 03 15:12:00 CST 2018, time=2018-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865166, encodeId=4861186516674, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu Aug 02 11:12:00 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010148, encodeId=21fa2010148f8, content=<a href='/topic/show?id=3ea49698234' target=_blank style='color:#2F92EE;'>#长期使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96982, encryptionId=3ea49698234, topicName=长期使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=365d170, createdName=chenwq08, createdTime=Sat Jan 27 11:12:00 CST 2018, time=2018-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749847, encodeId=e9841e498476f, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Thu Oct 04 06:12:00 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410723, encodeId=d5e81410e23f0, content=<a href='/topic/show?id=a30f9694596' target=_blank style='color:#2F92EE;'>#长效胰岛素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96945, encryptionId=a30f9694596, topicName=长效胰岛素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0de12767699, createdName=zz71, createdTime=Thu Oct 26 06:12:00 CST 2017, time=2017-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255658, encodeId=049a25565895, content=学习了.谢谢., beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Tue Oct 24 19:20:27 CST 2017, time=2017-10-24, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1826387, encodeId=da74182638ea9, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Jul 03 15:12:00 CST 2018, time=2018-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865166, encodeId=4861186516674, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu Aug 02 11:12:00 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010148, encodeId=21fa2010148f8, content=<a href='/topic/show?id=3ea49698234' target=_blank style='color:#2F92EE;'>#长期使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96982, encryptionId=3ea49698234, topicName=长期使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=365d170, createdName=chenwq08, createdTime=Sat Jan 27 11:12:00 CST 2018, time=2018-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749847, encodeId=e9841e498476f, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Thu Oct 04 06:12:00 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410723, encodeId=d5e81410e23f0, content=<a href='/topic/show?id=a30f9694596' target=_blank style='color:#2F92EE;'>#长效胰岛素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96945, encryptionId=a30f9694596, topicName=长效胰岛素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0de12767699, createdName=zz71, createdTime=Thu Oct 26 06:12:00 CST 2017, time=2017-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255658, encodeId=049a25565895, content=学习了.谢谢., beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Tue Oct 24 19:20:27 CST 2017, time=2017-10-24, status=1, ipAttribution=)]
    2018-08-02 minlingfeng
  3. [GetPortalCommentsPageByObjectIdResponse(id=1826387, encodeId=da74182638ea9, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Jul 03 15:12:00 CST 2018, time=2018-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865166, encodeId=4861186516674, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu Aug 02 11:12:00 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010148, encodeId=21fa2010148f8, content=<a href='/topic/show?id=3ea49698234' target=_blank style='color:#2F92EE;'>#长期使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96982, encryptionId=3ea49698234, topicName=长期使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=365d170, createdName=chenwq08, createdTime=Sat Jan 27 11:12:00 CST 2018, time=2018-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749847, encodeId=e9841e498476f, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Thu Oct 04 06:12:00 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410723, encodeId=d5e81410e23f0, content=<a href='/topic/show?id=a30f9694596' target=_blank style='color:#2F92EE;'>#长效胰岛素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96945, encryptionId=a30f9694596, topicName=长效胰岛素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0de12767699, createdName=zz71, createdTime=Thu Oct 26 06:12:00 CST 2017, time=2017-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255658, encodeId=049a25565895, content=学习了.谢谢., beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Tue Oct 24 19:20:27 CST 2017, time=2017-10-24, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1826387, encodeId=da74182638ea9, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Jul 03 15:12:00 CST 2018, time=2018-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865166, encodeId=4861186516674, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu Aug 02 11:12:00 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010148, encodeId=21fa2010148f8, content=<a href='/topic/show?id=3ea49698234' target=_blank style='color:#2F92EE;'>#长期使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96982, encryptionId=3ea49698234, topicName=长期使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=365d170, createdName=chenwq08, createdTime=Sat Jan 27 11:12:00 CST 2018, time=2018-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749847, encodeId=e9841e498476f, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Thu Oct 04 06:12:00 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410723, encodeId=d5e81410e23f0, content=<a href='/topic/show?id=a30f9694596' target=_blank style='color:#2F92EE;'>#长效胰岛素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96945, encryptionId=a30f9694596, topicName=长效胰岛素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0de12767699, createdName=zz71, createdTime=Thu Oct 26 06:12:00 CST 2017, time=2017-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255658, encodeId=049a25565895, content=学习了.谢谢., beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Tue Oct 24 19:20:27 CST 2017, time=2017-10-24, status=1, ipAttribution=)]
    2018-10-04 baoya
  5. [GetPortalCommentsPageByObjectIdResponse(id=1826387, encodeId=da74182638ea9, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Jul 03 15:12:00 CST 2018, time=2018-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865166, encodeId=4861186516674, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu Aug 02 11:12:00 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010148, encodeId=21fa2010148f8, content=<a href='/topic/show?id=3ea49698234' target=_blank style='color:#2F92EE;'>#长期使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96982, encryptionId=3ea49698234, topicName=长期使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=365d170, createdName=chenwq08, createdTime=Sat Jan 27 11:12:00 CST 2018, time=2018-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749847, encodeId=e9841e498476f, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Thu Oct 04 06:12:00 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410723, encodeId=d5e81410e23f0, content=<a href='/topic/show?id=a30f9694596' target=_blank style='color:#2F92EE;'>#长效胰岛素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96945, encryptionId=a30f9694596, topicName=长效胰岛素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0de12767699, createdName=zz71, createdTime=Thu Oct 26 06:12:00 CST 2017, time=2017-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255658, encodeId=049a25565895, content=学习了.谢谢., beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Tue Oct 24 19:20:27 CST 2017, time=2017-10-24, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1826387, encodeId=da74182638ea9, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Jul 03 15:12:00 CST 2018, time=2018-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865166, encodeId=4861186516674, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu Aug 02 11:12:00 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010148, encodeId=21fa2010148f8, content=<a href='/topic/show?id=3ea49698234' target=_blank style='color:#2F92EE;'>#长期使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96982, encryptionId=3ea49698234, topicName=长期使用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=365d170, createdName=chenwq08, createdTime=Sat Jan 27 11:12:00 CST 2018, time=2018-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749847, encodeId=e9841e498476f, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Thu Oct 04 06:12:00 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410723, encodeId=d5e81410e23f0, content=<a href='/topic/show?id=a30f9694596' target=_blank style='color:#2F92EE;'>#长效胰岛素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96945, encryptionId=a30f9694596, topicName=长效胰岛素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0de12767699, createdName=zz71, createdTime=Thu Oct 26 06:12:00 CST 2017, time=2017-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255658, encodeId=049a25565895, content=学习了.谢谢., beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Tue Oct 24 19:20:27 CST 2017, time=2017-10-24, status=1, ipAttribution=)]
    2017-10-24 惠映实验室

    学习了.谢谢.

    0

相关资讯

乳腺癌化疗精准之路,真实世界研究指明前进方向!

十六世纪,埃及出现了世界上第一个有记载的癌症病例——乳腺癌,一场与肿瘤对抗的大幕就此揭开。1942年,随着第一个抗肿瘤药物氮芥的发现,肿瘤内科治疗拉开了序幕。上世纪90年代起,紫杉类药物的卓越效果,奠定了辅助化疗的基石地位。近年来,随着内分泌靶向和免疫精准治疗的发展,乳腺癌的治愈不再遥不可及。10月21日,在第十二届上海国际乳腺癌论坛上,中国医学科学院肿瘤医院徐兵河教授以《鉴往知来——从中国临

张敬杰教授:绝经后激素受体阳性乳腺癌患者心血管风险的有效管理

乳腺癌居全球女性恶性肿瘤发病率之首,我国女性多在45~55岁之间自然绝经,45岁以上乳腺癌在我国占所有乳腺癌的三分之二。因此,国内超过半数的乳腺癌患者在发病时已处于围绝经期或绝经期。

[上海乳房重建论坛]厉红元教授:乳房重建,续写乳腺癌患者的美丽人生

随着诊疗技术的不断提高,乳腺癌患者在肿瘤控制的前提下进行乳房重建,可提高患者治疗依从性、重拾生活自信心。2017年10月19日,“第九届上海乳房重建论坛”成功举办。会议期间,《肿瘤了望》采访了重庆医科大学附属第一医院厉红元教授,探讨乳腺癌患者术后乳房重建如何实现安全与美观兼得。

Nature+Nat Genetics:75个与乳腺癌风险相关的新位点被发现

本周《自然》和《自然-遗传学》发表两篇论文Association analysis identifies 65 new breast cancer risk loci和Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer介绍了与乳腺癌风险上升相关的遗传变异。人们

[SIBCS2017]柳光宇教授:“三阴”并非早期乳腺癌患者保乳手术的禁忌

与老百姓谈癌色变相仿,论及三阴性乳腺癌时,乳腺科医生的心弦也会为之绷紧。第十二届上海乳腺癌论坛中也就三阴乳腺癌的保乳治疗和化疗等问题展开专场讨论。《肿瘤了望》采访了主持该讨论会的复旦大学附属肿瘤医院柳光宇教授,就此问题再做阐述。

吴炅教授:在协作中完成乳腺癌乳房重建

乳腺癌术后乳房重建作为乳腺癌综合治疗的重要组成部分,其地位正不断凸显。中国乳腺癌诊治领域的专家正不懈努力地推广和提高乳腺癌乳房重建技术。2017年10月18~19日,第九届上海乳房重建论坛成功举办。《肿瘤了望》特邀大会主席复旦大学附属肿瘤医院吴炅教授对中国乳腺癌乳房重建现状及未来进行了回顾和展望。